ARA-290 Dosage Guide: How Much Should You Take? (2026)

ARA-290 Dosage Guide: How Much Should You Take? (2026)

Key Takeaways

• Standard Dosage Range: ARA-290 is typically administered at doses ranging from 4 mg to 8 mg, depending on the therapeutic goal and patient response.
• Administration Method: Primarily administered via subcutaneous injection due to its bioavailability and targeted delivery.
• Typical Cycle Length: Treatment cycles can vary from 4 to 12 weeks, with adjustments based on individual response and clinical objectives.
• Regulatory Status: ARA-290 is not FDA-approved for therapeutic use; it is available for research purposes only.
• Medical Supervision: Due to its research status, ARA-290 should be used under the guidance of a qualified healthcare provider.

How ARA-290 Works in the Body

ARA-290 is a synthetic peptide derived from the B-helix domain of erythropoietin, designed to interact with the EPOR–CD131 receptor complex. This interaction activates the innate repair receptor (IRR) pathway, promoting tissue protection without stimulating erythropoiesis. The specificity of ARA-290 for this receptor complex is crucial in its therapeutic applications, particularly in modulating inflammatory responses and protecting neural tissues.

The pharmacokinetic properties of ARA-290, such as its half-life and bioavailability, significantly impact dosing decisions. ARA-290 exhibits a relatively short half-life, necessitating frequent administration to maintain therapeutic levels. Its bioavailability is optimal when administered subcutaneously, allowing for direct absorption into the bloodstream.

Clinical studies have explored ARA-290's efficacy in various conditions. For instance, a study published in Molecular Medicine (PMID 25387363) demonstrated its potential in improving metabolic control and neuropathic symptoms in type 2 diabetes patients. Similarly, research published in Molecular Pain (PMID 24529189) highlighted its ability to provide long-term relief of neuropathic pain.

"ARA-290, a nonerythropoietic peptide engineered from erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection." — Molecular Medicine (PMID 25387363)

Standard ARA-290 Dosage Ranges (By Form)

Subcutaneous Administration

• Dosage Range: 4 mg to 8 mg per administration
• Frequency: Typically administered once daily
• Bioavailability: High, due to direct absorption into the bloodstream
• Commonality: Subcutaneous injection is the preferred form due to its efficacy and ease of use.

Intramuscular Administration

• Dosage Range: Similar to subcutaneous, but less commonly used
• Frequency: Once daily or as directed by a healthcare provider
• Bioavailability: Slightly lower than subcutaneous administration

Oral and Other Forms

Currently, ARA-290 is primarily available as a lyophilized powder for research use, with subcutaneous injection being the most common administration route. Oral and other forms are not widely utilized due to reduced bioavailability and lack of clinical validation.

ARA-290 Dosage by Use Case

Neuropathic Pain Management

• Typical Dosage Range: 4 mg to 6 mg subcutaneously
• Administration Method: Subcutaneous injection
• Cycle Length: 8 to 12 weeks
• Study Reference: A study in Molecular Pain (PMID 24529189) supports its use for neuropathic pain relief.

Inflammation Modulation

• Typical Dosage Range: 4 mg to 8 mg subcutaneously
• Administration Method: Subcutaneous injection
• Cycle Length: 4 to 8 weeks
• Study Reference: Research in Brain, Behavior, and Immunity (PMID 34343617) explores its role in modulating inflammation.

Metabolic Control in Diabetes

• Typical Dosage Range: 4 mg subcutaneously
• Administration Method: Subcutaneous injection
• Cycle Length: 12 weeks
• Study Reference: Molecular Medicine (PMID 25387363) highlights its efficacy in metabolic control.

How Long Should You Take ARA-290?

The duration of ARA-290 therapy depends on the specific therapeutic goal and individual patient response. Typical treatment cycles range from 4 to 12 weeks. During the initial week, patients may begin to notice subtle improvements, with more pronounced effects emerging between weeks 2 to 4. By week 6 and beyond, many patients report significant symptom relief.

Tapering off ARA-290 is generally not required due to its short half-life. However, discontinuation should be managed by a healthcare provider to monitor any potential return of symptoms.

Administration Protocol: How to Take ARA-290

Injection Technique

• Needle Gauge: Use a 27-30 gauge needle for subcutaneous injections.
• Injection Sites: Rotate between the abdomen, thigh, and upper arm to prevent tissue damage.
• Rotation Schedule: Rotate injection sites daily to minimize local irritation and improve absorption.

Storage Requirements

• Temperature: Store lyophilized powder at 2-8°C (36-46°F).
• Light Sensitivity: Protect from light to maintain stability.
• Reconstituted Stability: Use reconstituted solution within 24 hours if stored at room temperature.

Reconstitution Instructions

For detailed reconstitution instructions, refer to our reconstitution guide.

Administration Process

1. Preparation: Wash hands and gather all necessary supplies.
2. Reconstitution: Mix the lyophilized powder with the appropriate diluent.
3. Injection: Clean the injection site with an alcohol swab, pinch the skin, and inject at a 45-degree angle.
4. Post-Injection: Apply gentle pressure with a cotton ball or gauze.

Stacking ARA-290 for Better Results

ARA-290 and BPC-157

• Combination: ARA-290 (4 mg) with BPC-157 (250 mcg)
• Dosing Synergy: Enhances tissue repair and reduces inflammation
• Common Protocols: Used in protocols for sports injuries and chronic pain management
• Link: BPC-157

ARA-290 and TB-500

• Combination: ARA-290 (4 mg) with TB-500 (2 mg)
• Dosing Synergy: Promotes healing and reduces fibrosis
• Common Protocols: Often used in protocols for fibrotic conditions
• Link: TB-500

Factors That Affect Your ARA-290 Dosage

Several factors can influence the optimal dosage of ARA-290, including:

• Body Weight: Heavier individuals may require higher doses.
• Age: Older patients may have altered pharmacokinetics.
• Treatment Goals: Specific conditions may dictate different dosing.
• Kidney/Liver Function: Impaired function can affect metabolism and clearance.
• Other Medications: Potential interactions may necessitate dosage adjustments.
• Individual Response: Variability in response requires personalized dosing.

Common Dosing Mistakes to Avoid

1. Dosing Too High/Too Low: Follow prescribed dosages to avoid adverse effects or suboptimal efficacy.
2. Inconsistent Timing: Administer at the same time daily to maintain stable blood levels.
3. Wrong Injection Site: Use appropriate sites to optimize absorption.
4. Not Accounting for Regulatory Status: Remember that ARA-290 is for research only.
5. Poor Storage/Handling: Store and handle properly to maintain peptide integrity.

What the Evidence Does Not Show

While ARA-290 shows promise in preclinical and early clinical studies, there are limitations to the current evidence:

• Long-Term Safety Data: Comprehensive long-term studies are lacking.
• Human Trials: Most data are from preclinical or early-phase trials.
• Dose-Response Data: Limited information on optimal dosing for various conditions.

FAQ — Your Top ARA-290 Dosage Questions Answered

Best time of day to take it?
ARA-290 can be administered at any time, but consistency is key. Choose a time that fits your schedule.

What if you miss a dose?
If you miss a dose, take it as soon as you remember unless it's close to your next scheduled dose. Do not double up.

Can men and women use the same dose?
Yes, dosing is not typically gender-specific but should be personalized based on individual factors.

Can you stack it with other peptides?
Yes, ARA-290 is often stacked with peptides like BPC-157 and TB-500 for enhanced effects.

How long until you see results?
Results vary, but many patients report improvements within 2-4 weeks.

Do you need to cycle off?
Cycling off is generally not required, but follow your healthcare provider's recommendations.

Is a loading dose needed?
A loading dose is not typically necessary for ARA-290.

How to adjust dose if side effects occur?
Consult your healthcare provider to adjust dosing if side effects are experienced.

Conclusion — Finding the Right Dosage for You

Determining the appropriate ARA-290 dosage involves considering various factors, including therapeutic goals and individual response. It is crucial to work with a healthcare provider to tailor the dosage to your specific needs. For more information on peptides and their applications, explore our peptide encyclopedia and treatment guides.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Dosage information is compiled from published research and clinical protocols. Consult a licensed healthcare provider before starting any peptide therapy. Use our clinic finder to locate a qualified provider near you.